AbbVie (ABBV): Harvest Portfolios Group Inc. reduced its stake -6,573 shares
Harvest Portfolios Group Inc. reduced its stake in AbbVie, per its Q4 2025 13F.
- 279K
- Shares reported · -6,573 vs prior quarter
- 1.1%
- Disclosed portfolio weight
- $63.7M
- Reported value
- Holdings as of
- Dec 31, 2025
- Filed
- Feb 6, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 23, 2024CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
- Jan 24, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
- Apr 28, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
- Nov 13, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
- Dec 8, 2025Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.8K obligated to date
- Dec 8, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
- Dec 12, 2025Federal contract · $24K obligatedDepartment of Defense awarded AbbVie: $24K obligated to date
- Dec 18, 2025FDAFDA drug approval: Vraylar
- Dec 18, 2025FDAFDA drug approval: Vraylar
- Dec 18, 2025FDAFDA drug approval: Vraylar
- Dec 18, 2025FDAFDA drug approval: Vraylar
- Dec 18, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
- Dec 22, 2025Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Institution of Investigation
- Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
- Jan 16, 2026FDAFDA device clearance: Natrelle 133S Tissue Expanders
- Jan 20, 2026Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $4K obligated to date
- Feb 3, 2026Federal contract · $5K obligatedDepartment of Defense awarded AbbVie: $4.6K obligated to date
- Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
What came next
- Feb 19, 2026FDAFDA drug approval: Venclexta
- Feb 25, 2026Insider · Their largest sale since 2023Officer sold ~$5.15M of ABBV shares in the open market
- Mar 2, 2026Insider · 1 personInsiders: 3 sales (~$4.4M)
- Mar 4, 2026InsiderOfficer sold ~$1.22M of ABBV shares in the open market
- Mar 5, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.4K obligated to date
- Mar 6, 2026FDAFDA drug approval: Skyrizi
- Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
- Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Apr 3, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 23, 2026Government · Federal Register noticeKimberly Schaff Kiehl: Final Debarment Order
- Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- May 5, 2026CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
- May 18, 2026FDARecall: PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product…
- May 19, 2026Layoff notice · 2525 Dupont Drive Irvine CA 92612Layoff notice filed in CA: 85 employees
- May 20, 2026FDAFDA drug approval: Venclexta
- May 21, 2026FDAFDA drug approval: Linzess
- May 27, 2026FDAFDA drug approval: Decnupaz
- Jun 3, 2026Government · Federal Register noticeElite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for AbbVie
For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.
How this filing works
Explore the data
Common questions
What does this filing report about AbbVie (ABBV) stock?
Harvest Portfolios Group Inc. reduced its stake in AbbVie, per its Q4 2025 13F. Now 279K shares, $63.7M reported value, 1.1% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Dec 31, 2025. Filed: Feb 6, 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about AbbVie recently?
For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.
Does this mean ABBV stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at AbbVie
- SEC Form 144Nov 16, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 12, 2026
- SEC Form 144Nov 9, 2026
- House Clerk periodic transaction reportSep 18, 2026
- SEC Form 13F-HRAug 26, 2026
Everything OQRO holds on this company is on its ABBV page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
